| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 11% | $343,082,387 | 17,540,089 | T. Rowe Price Investment Management, Inc. | 31 Dec 2025 | |||
| JANUS HENDERSON GROUP PLC | 8.5% | -19% | $251,645,523 | -$15,543,028 | 13,887,722 | -5.8% | JANUS HENDERSON GROUP PLC | 31 Dec 2025 |
| BlackRock, Inc. | 5.8% | $73,080,236 | 6,577,879 | BlackRock, Inc. | 31 Mar 2025 | |||
| Atlas Venture Fund XI, L.P. | 4% | $72,275,396 | 5,713,470 | Atlas Venture Associates XI, L.P. | 30 Sep 2025 | |||
| Forbion Capital Fund IV Cooperatief U.A. | 4.8% | $60,000,055 | 5,400,545 | ForDyne B.V. | 31 Mar 2025 | |||
| FMR LLC | 4.6% | -41% | $57,719,716 | -$31,126,187 | 5,195,294 | -35% | FMR LLC | 31 Mar 2025 |
| RTW INVESTMENTS, LP | 1.5% | -72% | $18,782,199 | -$39,196,902 | 1,690,567 | -68% | RTW Investments, LP | 31 Mar 2025 |
| Point72 Asset Management, L.P. | 1.5% | -72% | $18,546,390 | -$39,187,803 | 1,669,342 | -68% | Point72 Asset Management, L.P. | 31 Mar 2025 |
As of 31 Dec 2025, 228 institutional investors reported holding 177,803,689 shares of Dyne Therapeutics, Inc. - Common Stock (DYN). This represents 109% of the company’s total 163,384,965 outstanding shares.
The largest institutional shareholders of Dyne Therapeutics, Inc. - Common Stock (DYN) together control 83% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 11% | 17,540,089 | +524% | 0.22% | $343,085,000 |
| JANUS HENDERSON GROUP PLC | 8.5% | 13,887,722 | -5.8% | 0.12% | $271,603,659 |
| VANGUARD GROUP INC | 6.9% | 11,215,565 | +15% | 0% | $219,376,451 |
| BlackRock, Inc. | 6.8% | 11,190,838 | +16% | 0% | $218,892,793 |
| Atlas Venture Life Science Advisors, LLC | 5.6% | 9,130,465 | 0% | 21% | $178,591,895 |
| STATE STREET CORP | 4.1% | 6,692,745 | +27% | 0% | $130,910,092 |
| FMR LLC | 4% | 6,569,921 | +22% | 0.01% | $128,507,653 |
| FCPM III SERVICES B.V. | 3.3% | 5,462,846 | 0% | 14% | $106,853,268 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.2% | 5,172,000 | +46% | 0.15% | $101,164,320 |
| Orbis Allan Gray Ltd | 2.9% | 4,801,928 | 0.39% | $93,925,712 | |
| TCG Crossover Management, LLC | 2.8% | 4,615,144 | 0% | 3% | $90,272,217 |
| JPMORGAN CHASE & CO | 2.2% | 3,549,909 | +5.5% | 0% | $69,436,220 |
| Siren, L.L.C. | 2.1% | 3,502,941 | -26% | 2% | $68,517,526 |
| PERCEPTIVE ADVISORS LLC | 2.1% | 3,478,944 | +544% | 1.2% | $68,048,145 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 3,263,429 | +14% | 0% | $63,844,380 |
| ARMISTICE CAPITAL, LLC | 2% | 3,249,708 | +6.1% | 1.6% | $63,564,288 |
| Frazier Life Sciences Management, L.P. | 1.9% | 3,153,082 | +16% | 1.7% | $61,674,284 |
| Deep Track Capital, LP | 1.6% | 2,650,000 | +32% | 1.2% | $51,834,000 |
| Vivo Capital, LLC | 1.6% | 2,614,960 | 0% | 3.3% | $51,148,618 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.4% | 2,323,789 | +66% | 0% | $45,454,000 |
| GOLDMAN SACHS GROUP INC | 1.4% | 2,283,191 | +20% | 0.01% | $44,659,216 |
| Sofinnova Investments, Inc. | 1.4% | 2,254,161 | +129% | 1.9% | $44,091,389 |
| ORBIMED ADVISORS LLC | 1.3% | 2,202,184 | -4.8% | 0.92% | $43,074,719 |
| VR ADVISER, LLC | 1.3% | 2,173,913 | 0% | 2.1% | $42,521,738 |
| FRANKLIN RESOURCES INC | 1.2% | 2,006,638 | +43% | 0.01% | $39,249,837 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 177,803,689 | $3,477,723,511 | +$511,413,657 | $19.56 | 228 |
| 2025 Q3 | 155,774,921 | $1,970,440,035 | +$381,733,574 | $12.65 | 205 |
| 2025 Q2 | 128,553,808 | $1,223,875,095 | +$58,226,785 | $9.52 | 195 |
| 2025 Q1 | 121,788,688 | $1,284,331,056 | -$75,923,327 | $10.46 | 202 |
| 2024 Q4 | 111,635,776 | $2,630,327,572 | -$39,471,758 | $23.56 | 199 |
| 2024 Q3 | 112,428,939 | $4,033,469,001 | -$6,349 | $35.92 | 200 |
| 2024 Q2 | 110,972,098 | $3,915,861,443 | +$555,159,053 | $35.29 | 191 |
| 2024 Q1 | 95,365,001 | $2,707,385,907 | +$786,881,972 | $28.39 | 167 |
| 2023 Q4 | 69,922,072 | $929,957,219 | +$57,596,260 | $13.30 | 123 |
| 2023 Q3 | 59,888,832 | $536,594,556 | +$1,685,315 | $8.96 | 114 |
| 2023 Q2 | 59,189,838 | $665,851,766 | +$50,911,029 | $11.25 | 117 |
| 2023 Q1 | 54,627,733 | $628,721,822 | +$56,536,368 | $11.52 | 125 |
| 2022 Q4 | 49,732,095 | $576,377,450 | +$50,130,248 | $11.59 | 112 |
| 2022 Q3 | 44,533,854 | $565,571,380 | -$9,010,573 | $12.70 | 100 |
| 2022 Q2 | 46,679,856 | $320,706,640 | -$8,056,035 | $6.87 | 87 |
| 2022 Q1 | 47,256,134 | $455,432,690 | -$4,233,139 | $9.64 | 90 |
| 2021 Q4 | 47,794,946 | $568,260,037 | +$18,929,604 | $11.89 | 90 |
| 2021 Q3 | 32,306,202 | $524,727,164 | -$16,367,213 | $16.24 | 80 |
| 2021 Q2 | 35,805,078 | $753,366,735 | +$36,093,361 | $21.04 | 75 |
| 2021 Q1 | 31,379,394 | $487,292,000 | +$72,426,450 | $15.53 | 72 |
| 2020 Q4 | 26,339,155 | $552,433,805 | +$28,795,524 | $21.00 | 67 |
| 2020 Q3 | 24,527,914 | $493,744,000 | +$493,744,015 | $20.19 | 49 |